Low-dose recombinant factor VIIa for massive bleeding: A single centre observational cohort study with 73 patients
Journal article published in 2011 by
Pirmin Schmid,
Andrea Mordasini,
Martin Luginbühl,
Bruno Regli,
Hans-Peter Kohler,
Heinz Zimmermann,
Daniel Inderbitzin,
Andreas Hirt,
Bernhard Lämmle 
,
Lorenzo Alberio
,
Lorenzo Alberio
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
recombinant activated factor VII (rFVIIa) is used off-label for massive bleeding. There is no convincing evidence of the benefits of this practice and the minimal effective dose is unknown. The aim of the study was to evaluate our in-house guideline recommending a low dose of 60 μg/kg for off-label use of rFVIIa.